These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Guidelines for diagnosis, therapy and follow up of Anderson-Fabry disease.
    Author: Kes VB, Cesarik M, Zavoreo I, Soldo-Butković S, Kes P, Basić-Jukić N, Racki S, Jakić M, Delić-Brkljacić D, Jukić Z, Trkanjec Z, Serić V, Solter VV, Bielen I, Basić S, Demarin V, Croatian Society for Neurovascular Disorders of Croatian Medical Association, Croatian Society of Neuroimmunology and Neurogenetics, Croatian Society of Neurology of Croatian Medical Association, Croatian Society of Nephrology, Dialysis and Transplantation of Croatian Medical Association.
    Journal: Acta Clin Croat; 2013 Sep; 52(3):395-405. PubMed ID: 24558776.
    Abstract:
    Fabry disease (Anderson-Fabry disease) is one of the most common lysosomal storage diseases (after Gaucher disease) caused by deficient activity of the alpha-galactosidase A (alpha-Gal A) enzyme, which leads to progressive accumulation of globotriaosylceramide in various cells, predominantly in endothelium and vascular smooth muscles, with multisystem clinical manifestations. Estimates of the incidence range from one per 40,000 to 60,000 in males, and 1:117,000 in the general population. Pain is usually the first symptom and is present in 60%-80% of affected children, as well as gastrointestinal disturbances, ophthalmologic abnormalities and hearing loss. Renal failure, hypertrophic cardiomyopathy, or stroke as the presenting symptom may also be found even as isolated symptoms of the disease. Life expectancy is reduced by approximately 20 years in males and 10-15 years in females, therefore enzyme replacement therapy should be introduced in patients of any age and either sex, who meet treatment criteria for Anderson-Fabry disease.
    [Abstract] [Full Text] [Related] [New Search]